| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Stock warrant expense | 0 | 0 |
| Gain on forgiveness of ceba loan | 0 | - |
| Depreciation and amortization | 56 | 46 |
| Stock-based compensation expense | 547 | 405 |
| Change in fair value of warrant liabilities | 23 | 3 |
| Change in fair value of pipe notes | -1,221 | -1,221 |
| Change in fair value of yorkville note | 64 | 64 |
| Change in fair value of crypto assets bitcoin | -782 | -837 |
| Change in fair value of derivative liability | 32 | 434 |
| Realized gain on sale of crypto assets bitcoin | 899 | 844 |
| Gain on troubled debt restructurings | 5,569 | 3,707 |
| Loss on extinguishment of debt | -41 | 0 |
| Non-cash interest | 45 | 45 |
| Accounts receivable | 369 | 41 |
| Prepaid expenses and other current assets | -270 | -92 |
| Accounts payable and accrued expenses | 52 | -380 |
| Deferred revenues | 209 | -49 |
| Net income (loss) | 339 | 1,080 |
| Net cash used in operating activities | -5,790 | -4,232 |
| Purchases of property and equipment | 8 | 8 |
| Purchases of crypto assets bitcoin | 2,400 | 2,200 |
| Sales of crypto assets bitcoin | 4,766 | 3,458 |
| Net cash provided by (used in) investing activities | 2,358 | 1,250 |
| Proceeds from issuance of shareholder loans | 0 | 0 |
| Proceeds from issuance of yorkville note | 0 | 0 |
| Proceeds from line of credit borrowings | 0 | 0 |
| Repayment of shareholder loan | 0 | 0 |
| Repayment of line of credit borrowings | 0 | - |
| Repayment of deferred underwriter fees | 0 | 500 |
| Repayment of ceba loan | 0 | 0 |
| Proceeds from private placement, net of issuance costs | 2,497 | 2,497 |
| Proceeds from subscription agreements with related parties, net of issuance costs | 1,697 | 1,197 |
| Repayment of yorkville note | 262 | 262 |
| Repayment of deferred underwriter fees payable | 500 | - |
| Repayment of loan extensions | 12 | - |
| Repayment for common stock repurchase | 11 | - |
| Net cash provided by financing activities | 3,409 | 2,932 |
| Net (decrease) increase in cash and cash equivalents | -23 | -50 |
| Cash and cash equivalents at beginning of period | 172 | - |
| Cash and cash equivalents at end of period | 149 | - |
OneMedNet Corp (ONMDW)
OneMedNet Corp (ONMDW)